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Introduction 
With the use of high-resolution ultrasound (US) 
equipment and the recent introduction of supplementary 
screening breast US in a population with dense breasts 
and an elevated risk of breast cancer, the hypoechoic non-
mass lesions (NML) that do not meet the criteria of a mass 
defined by the American College of Radiology Breast 
Imaging Reporting And Data System (ACR BI-RADS) 
lexicon [1] are sometimes encountered [2-4]. It has been 
reported that these lesions on US can reflect a wide spec-
trum of pathologic changes such as fibrocystic change, fi-
brosis, mastitis, ductal carcinoma in situ (DCIS), invasive 
lobular carcinoma (ILC), or invasive ductal carcinoma 
(IDC) [3-12]. However, these NMLs are not included in 
the BI-RADS lexicon for breast US [1].
The Japanese Association of Breast and Thyroid So-
nology systematically organized and classified NMLs, first 
time in 2004 [2], but only a few studies have reported the 
imaging features and histologic characteristics of NMLs 
[3,6,13]. Moreover, no report has been published regard-
ing the incidence, BI-RADS categorization, and the guide-
lines for management of NMLs on screening breast US. 
Therefore, the purpose of this study was to investigate the 
incidence, histologic characteristics and US features of 
NMLs which were recognized during screening breast US 
and to determine the positive predictive value (PPV) of 
biopsy and the likelihood of malignancy of these features.
Materials and methods
Patients selection and inclusion criteria
Institutional review board approval was obtained 
for this retrospective study, and the informed consent 
was waived. A total of 17868 bilateral whole-breast 
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US screening were performed in 8856 asymptomatic 
women at our institution between March 2008 and June 
2012. Indications for screening breast US were as fol-
lows: asymptomatic patients with dense breast tissue on 
mammography, postoperative screening after surgery for 
breast cancer, and screening which is requested by pa-
tients themselves or physicians. Among these examina-
tions, 513 patients with NMLs were retrospectively iden-
tified through a search of our radiology database with 
a prospectively recorded NML. A non-mass lesion was 
defined as a hypoechoic area which does not conform to 
the definition of a “mass”, which is defined as a space-
occupying lesion seen in two different planes and it has 
different character from that of the surrounding paren-
chyma or the same area in the contralateral breast [2,3]. 
It may be analogous to a focal asymmetry on mammog-
raphy. Lesions showing the patterns of duct changes were 
excluded from this study. Among them, we excluded 388 
patients with a past history of biopsy or operation at the 
area of a NML and 37 patients with mammographic sus-
picious features of malignancy and finally, a total of 88 
patients with 95 lesions were included in this study. Sev-
en patients had two lesions. The patients ranged in age 
from 28 to 68 years, with a mean age of 48.2 years.
Image analysis
Bilateral whole-breast US examinations were per-
formed by one of two breast imaging radiologists with 
12 and 9 years of experience in breast US, respective-
ly. High-resolution units with 7-13-MHz or 5-12-MHz 
linear-array transducers (Sonoline Antares, Siemens, 
Issaquah, Wash; HDI-5000, Philips-ATL, Bothell, WA) 
were used. Grayscale US was first performed to evaluate 
the sonographic characteristics of NMLs. A minimum of 
2 orthogonal grayscale images of each lesion were ob-
tained. Extended field-of-view (FOV) technology was 
used when the lesion size exceeded the FOV of the probe. 
After that, power Doppler US was performed.
The management of NMLs was depended on opera-
tor experience and clinical judgement. When a NML was 
detected, short-term follow-up after 6 months or tissue 
diagnosis was recommended. The indications for tissue 
diagnosis were as follows: NMLs with more hypoechoic 
patterns, lesions with posterior shadowing, new or in-
creasing lesions compared with prior US images if avail-
able, lesions in high-risk women, patients’ preference or 
clinical request to perform a biopsy. In cases that these 
criteria were not met, short-term follow up after 6 months 
was recommended.
The retrospective review for the classification of US 
findings of NMLs was based on consensus between two 
dedicated breast radiologists (J.H.L. and S.M.B) and the 
readers were blinded to the final diagnosis. The lesions 
were classified into indistinct, geographic, and mottled 
groups by US patterns according to the antecedent stud-
ies about NMLs on breast US [2,3]. An indistinct pat-
tern was defined as a relatively uniform hypoechoic 
area whose margins were not clearly defined (fig 1a-b). 
A geographic pattern was defined as a confluent hypo-
echoic area with a cobblestone appearance including an 
aggregation of small, island-like low echoic areas (fig 
1c). A mottled pattern was defined as a number of small, 
island-like low echoic areas in the mammary parenchy-
ma (fig 1d). US distribution classified NMLs into focal 
and regional groups. A focal distribution was defined as 
a lesion which was scanned within the FOV of the linear 
probe and a regional distribution was defined as a lesion 
which exceeded the FOV and needed the use of extended 
FOV technology. The internal vascularity of the lesions 
on power Doppler images was classified into absent and 
present groups.
Establishment of the final diagnosis
The final diagnoses were based on pathology results 
and a clinical or sonographic follow-up for more than 12 
months. Pathologic results, whether obtained by US-guid-
ed core needle or excisional biopsy, were considered defin-
itive. US-guided biopsy was performed using a 14-gauge 
semi-automated core biopsy needle (Stericut coaxial; TSK 
Laboratory, Tochigi, Japan) or a handheld vacuum-assist-
ed device with an 8-gauge probe (Mammotome; Devicor 
Medical Products; Cincinnati, OH, USA). In cases of a 
high risk lesion diagnosed by core needle biopsy, surgical 
excision or handheld vacuum-assisted biopsy were  recom-
mended. Lesions placed into imaging surveillance were 
considered benign if they were stable for at least 12 months. 
Fig 1. Ultrasonic classification of non-mass lesions. Sonograms show indistinct (a,b), geographic (c), and mottled (d, Courtesy of 
Kim SJ, Busan, Republic of Korea) patterns. 
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We calculated the incidence, PPV of biopsy, and like-
lihood of malignancy in the NMLs on screening breast 
US.
Results 
The incidence of the NML on screening breast US 
was one percent (95 lesions in 88 patients from a total 
of 8856 patients) at a single institution. Figure 2 shows 
the follow-up and pathology results. The mean follow-up 
interval was 33 months, with a range of 0~84 months and 
two patients with two lesions were lost to follow-up. All 
sixty-one lesions that were followed did not change or 
decrease in size during follow-up. US -guided core nee-
dle biopsy was performed in 32 lesions and among them, 
28 were benign, 2 were high risk lesions and 2 were ma-
lignant. In cases of high risk lesions, further treatment in-
cluding a vacuum-assisted biopsy and excision was per-
formed and they were finally confirmed as atypical ductal 
hyperplasia and intraductal papilloma, respectively. 
Therefore, among the 93 lesions which were con-
firmed by imaging follow-up or pathology, 2 were malig-
nant and the likelihood of malignancy was 2.2% and the 
PPV of biopsy was 6.3%. Table I demonstrates the his-
Fig 2. Algorithm that shows follow-up and pathology results.
Fig 3. A 51-year old woman presented for screening examina-
tion. Grayscale US showed a non-mass lesion with an indistinct 
pattern and a focal distribution at the 10 o’clock position in the 
right breast (a). On power Doppler image, internal vascularity 
was not noted in this lesion (b). Fibrocystic change with marked 
fibrosis was confirmed by a US-guided core needle biopsy.
Fig 4. A 52-year-old asymptomatic woman, who had un-
dergone a mastectomy for contralateral breast cancer 3 years 
ago. Postoperative screening US demonstrated a non-mass le-
sion showing an indistinct pattern and focal distribution at the 
2 o’clock position in the right breast (a). Internal vascularity 
was observed on a power Doppler image (b). A ductal carci-
noma in situ was confirmed by a US-guided core needle biopsy 
and a subsequent mastectomy was performed.
Fig 5. A 55-year-old asymptomatic woman presented for 
screening examination. Screening US demonstrated a non-mass 
lesion showing an indistinct pattern and a focal distribution at 
the 12 o’clock position in the left breast (a). Internal vascular-
ity was observed on a power Doppler image (b). An intraductal 
papillary carcinoma was confirmed by a US-guided core needle 
biopsy and a subsequent breast conserving surgery was per-
formed.
Table I. Histological characteristics of the pathologically con-
firmed non-mass lesions
Histological Characteristics (n = 32) No.






Diabetic fibrous mastopathy 2
Sclerosing adenosis 2
Stromal fibrosis 2
Chronic periductal inflammation 1
Lactation foci 1
Pseudoangiomatous stromal hyperplasia 1
Atypical ductal hyperplasia 1
Intraductal papilloma 1
Malignant (n = 2)
Ductal carcinoma in situ 1
Intraductal papillary carcinoma 1
Note – Data are the number of lesions.
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tological characteristics of the pathologically confirmed 
lesions. The fibrocystic change was the most common 
benign histology (fig 3). Two cases of malignant lesions 
were a case of DCIS (fig 4) and a case of intraductal 
papillary carcinoma (fig 5). The patient with DCIS had a 
past history of breast cancer surgery on her contralateral 
breast and the lesion was detected as a new one during 
postoperative screening US. The other patient was an 
asymptomatic patient with average risk factors.
In US image classification, the most common type 
was an indistinct pattern (81.7%, 76 of 93), a focal distri-
bution (95.7%, 89 of 93), absent vascularity (72.2%, 57 
of 79) (Table II). Both malignant lesions showed indis-
tinct patterns, focal distributions and presence of internal 
vascularity. 
Discussions
Some clinical trials and observational studies have 
evidenced that supplemental screening breast US in con-
junction with mammography have increased the cancer 
detection yield by 2.02–4.2 cancers per 1000 women 
over that of mammography alone. It is beneficial for 
detecting small size cancers when they are at an earlier 
stage rather than they would have been if they had been 
detected later as interval cancers [14,15]. However, the 
detection of additional cancers is associated with a sub-
stantial callback rate as well as an increased false posi-
tive biopsy rate [16]. Several studies show low PPV and 
do not meet the 25-40% PPV of biopsy recommended 
by the US agency for Health care Policy and Research 
[14]. Advances in US image quality and increasing util-
ity of bilateral whole breast US have allowed the detec-
tion of a hypoechoic area that does not meet the criteria 
of a mass in clinical settings and they include various 
spectrum, such as duct changes, architectural distortion, 
and non-mass lesions. However, as the current ACR BI-
RADS lexicon only covers mass lesions and a standard-
ized method for categorization of a NML does not exist, 
radiologists may recommend a follow-up or biopsy for 
these lesions based only on their experience. As a result, 
it may affect the sensitivity, specificity, recall rate and 
PPV of screening breast US.
There have been a few studies regarding NMLs on 
breast US [3-6,13] and all of these studies had different 
inclusion criteria. Morishima et al [13] reported the so-
nographic characteristics of breast cancer that showed 
NMLs. Kim et al [3] focused only on a NML showing 
a nonductal hypoechoic area which was similar to that 
in our study and Ko et al [6] included various spectrum 
of NMLs including a non-ductal pattern, duct changes, 
architectural distortion, and posterior shadowing type. 
Ko et al [5] reported the potential role of shear-wave 
elastography for the analysis of pathologically confirmed 
NMLs. All of these studies included both screening and 
diagnostic US examinations. In two studies that com-
pared imaging and clinical features of benign and malig-
nant NMLs, Kim et al [3] reported that malignant NMLs 
more frequently had densities and calcifications on 
mammography and palpability on physical examination 
(p=.0052, p<0.0001, p<0.0001, respectively). Ko et al 
[6] reported that NMLs with mammographic findings of 
suspected malignancy or presence of abnormal axillary 
nodes had a higher probability of malignancy (p<0.001 
and p<0.03, respectively). These results mean that a ma-
lignant NML is significantly associated with the presence 
of mammographic suspicious features of malignancy or 
clinical symptoms. In other words, the predominant fac-
tors which affect the management of sonographic NMLs 
such as biopsy or follow-up are not US features but mam-
mographic or clinical findings. Therefore, it is necessary 
to investigate the histologic characteristics and the like-
lihood of malignancy associated with these features of 
NMLs on screening breast US in patients with no mam-
mographic features suspicious for malignancy.
In our study population, the incidence of NMLs was 
1% and different from the incidences reported in two pre-
vious studies, which were 5.3% and 0.28%, respectively. 
The variability in the incidence rate is thought to be due 
to a difference in inclusion criteria among studies. The 
likelihood of malignancy was 2.2% (2 of 93) and it may 
be classified as a BI-RADS category 4a lesion and tissue 
diagnosis is warranted, although this study had a small 
population of patients. It is not possible to compare the 
likelihood of malignancy with that in previous studies, 
9.2% (30 of 156) in the study by Kim et al [3], 27% (38 
of 164) in the study by Ko et al [6], and 35% (12 of 34) 
in the study by Ko et al [5], because the present study 
which included only screening patients with negative 
findings on mammography had a different study popula-
Table II. US features of non-mass lesions
Non-mass lesions (n = 93) Number (%)




US distribution (n = 93)
Focal 89(95.7)
Regional 4(4.3)
Power Doppler signal (n = 79)
Absent           57(72.2)
Present 22(27.8)
Note – Data are the number of lesions.
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tion. The PPV of biopsy for NMLs in this study was 6.3% 
and it was similar to the PPV range of screening breast 
ultrasound that have been reported over the recent years, 
which ranged from 6.5% to 10.5% [17-21].
In the present study the management of NMLs was 
determined by operator experience and clinical judge-
ment because there is no standardized guideline for the 
interpretation of NMLs. Although we recommended tis-
sue diagnosis for NMLs according to our own criteria, 
the US features of two malignant lesions did not match 
up the criteria for biopsy recommendation. In other 
words, we recommended biopsy in cases of NMLs show-
ing more hypoechoic patterns or posterior shadowing. 
However, all malignant lesions evidenced a mild hypo-
echoic pattern and no posterior features. In one of the 
malignant cases, the reason for biopsy recommendation 
was that the NML was a new lesion during postopera-
tive screening US in a high risk patient with a history of 
contralateral breast cancer surgery. The other malignancy 
was initially assessed as category 3 and follow-up US 
after 6 months was recommended. But, biopsy was per-
formed due to the patient’s request. Therefore, further in-
vestigation will be required to establish the management 
guidelines for NMLs.
Fibrocystic change was the most common benign 
pathology (26.7%, 8 of 30) and this finding was simi-
lar to the results of the two previous studies [3,6]. Two 
malignant lesions were intraductal carcinomas which is 
not an invasive carcinoma. DCIS lesions have been re-
ported to be identified as NMLs of ductal or non-ductal 
pattern with or without echogenic spots corresponding 
to the mammographic findings [7,8] and Shin et al [9] 
reported that 17 of 106 DCIS lesions (16%) were shown 
as NML on screening detected DCIS. ILC also may not 
form a mass because it is composed of non-cohesive cells 
individually dispersed or arranged in a single-file linear 
pattern within fibrous stroma [4,10]. In Selinko et al se-
ries [12], 15% of ILC were described as an ill-defined 
area of altered, hypoechoic, inhomogeneous echotexture 
without identifiable margins and without frank shadow-
ing. Therefore, careful categorization and management 
of NMLs are needed in spite of the low likelihood of ma-
lignancy.
Although we analyzed the US features of NMLs, we 
could not compare between the benign and malignant 
groups statistically because of the small sample size. 
The most common group was indistinct pattern (81.7%), 
which is consistent with that of a previous study [3]. Two 
malignant cases showed internal vascularity in power 
Doppler images.  There was overlap in the Doppler sig-
nals between benign and malignant lesions, but Doppler 
can detect neovascularization which is an important role 
in the growth and extension of malignant neoplasm [22]. 
Furthermore, several studies reported that shear-wave 
elastographic features may be helpful for increasing the 
PPV of biopsy and reducing the number of unnecessary 
benign biopsies for NMLs [5,23] although we could  not 
utilize shear-wave elastography to characterize them. 
Therefore, biopsy burden in NMLs could be amended by 
the complementary use of Doppler US image or shear-
wave elastography. Also the use of the breast MRI might 
also be helpful.
This study had some limitations. Firstly, we had a 
small sample population with 93 NMLs including only 
two malignant lesions and it was not possible to perform 
a comparative analysis between the benign and malig-
nant groups. Secondly, this study was retrospective and 
included the opportunistic screening population in one 
institution and there may have been a selection bias. 
Thirdly, the determination of NMLs on US has inher-
ent subjectivity and can be highly operator dependent. 
Finally, we did   not utilize shear-wave elastography to 
characterize the breast lesions.
Conclusion
The incidence of non-mass lesions which is recog-
nized during screening breast ultrasound was 1.0% and 
the likelihood of malignancy was greater than 2%. It 
could be classified as a BI-RADS category 4a lesion and 
tissue diagnosis is warranted. However, further prospec-
tive studies in a large, multicenter screening population 
are required to establish which management recommen-
dation is most appropriate for the NMLs on screening 
breast US. 
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